[Cough, bronchoconstriction and bronchial hyperreactivity in relation to treatment with angiotensin-converting enzyme].
In the paper available information concerning the influence of treatment with angiotensin converting enzyme inhibitors (ACE-I) on cough, bronchial hyperreactivity and bronchoconstriction are reviewed. Cough occurs in 0.7% to 19% of patients treated with angiotensin converting enzyme inhibitors according to various reports. In the mechanism of angiotensin converting enzyme inhibitor-induced cough accumulation of bradykinin and substance P due to decreased degradation of this mediators caused by ACE-I may be involved. Part of tussive effect may be mediated via prostaglandins and histamine. In a few studies symptoms of airway obstruction and asthma worsening in relation to treatment with this drugs was reported. However, majority of reports suggest safety in taking ACE-I by patients with asthma. The only effective method to relieve angiotensin converting enzyme-induced cough is a drug withdrawal. The change of drugs within the whole class of ACE-I does not bring effect.
Szmidt
M
M
II Kliniki Gruzlicy i Chorób Płuc Instytutu Gruzlicy i Chorób Płuc w Lodzi.
Minc
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001920:Bradykinin / Q000378:metabolism; D016535:Bronchial Hyperreactivity / Q000139:chemically induced*; D001986:Bronchial Spasm / Q000139:chemically induced*; D003371:Cough / Q000139:chemically induced*; D006632:Histamine / Q000378:metabolism; D006801:Humans; D011453:Prostaglandins / Q000378:metabolism; D013373:Substance P / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D011453:Prostaglandins; D013373:Substance P; D006632:Histamine; D001920:Bradykinin
Kaszel, obturacja i nadreaktywność oskrzeli podczas stosowania inhibitorów konwertazy angiotensyny.